gms | German Medical Science

78. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

16.05. - 20.05.2007, München

Effect of Atorvastatin on progression of sensorineural hearing loss and tinnitus in the elderly: results of a prospective, randomized, double-blind clinical trial

Meeting Abstract

Suche in Medline nach

  • corresponding author Bernhard Olzowy - LMU München, HNO-Klinik, München, Germany
  • Martin Canis - LMU München, HNO-Klinik, München, Germany
  • Martin Hempel - LMU München, HNO-Klinik, München, Germany
  • Markus Suckfüll - LMU München, HNO-Klinik, München, Germany

German Society of Oto-Rhino-Laryngology, Head and Neck Surgery. 78th Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery. Munich, 16.-20.05.2007. Düsseldorf, Köln: German Medical Science; 2007. Doc07hno007

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/hno2007/07hno007.shtml

Veröffentlicht: 8. August 2007

© 2007 Olzowy et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: Both experimental and clinical evidence suggests that elevated serum cholesterol promotes development of sensorineural hearing loss. HMG-CoA reductase inhibitors have proven to be effective against high serum cholesterol. We therefore aimed to test, whether the HMG-CoA reductase inhibitor Atorvastatin can slow down the progression of chronic sensorineural hearing loss in the elderly.

Patients: 50 Patients, 60–75-years-old with presbycusis and moderately elevated serum cholesterol.

Intervention(s): In a double-blind design according to GCP patients were randomly assigned to treatment with either atorvastatin (40 mg orally per day) or placebo.

Main Outcome Measures: Pure tone audiometry and tinnitus evaluation at enrolment and after 7 and 13 months.

Results: Development of hearing thresholds after 7 and 13 months showed no significant differences between the groups. Tinnitus score continuously improved in the atorvastatin group (34.8 at 7, 27.6 at 13 months) while it slightly deteriorated in the placebo group (24.8 at 7, 26.8 at 13 months). The effect on tinnitus was a tendency without statistic significance (p=0.0833).

Conlusions: Atorvastatin had no effect on the development of hearing thresholds, but resulted in a trend towards a relief of tinnitus.